<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Vesta Teleradiology | freestyle libre</title>
	<atom:link href="https://vestarad.com/tag/freestyle-libre/feed/" rel="self" type="application/rss+xml" />
	<link>https://vestarad.com</link>
	<description>Remote Radiology Reading Services</description>
	<lastBuildDate>Tue, 04 Mar 2025 00:13:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://vestarad.com/wp-content/uploads/2019/06/favicon.png</url>
	<title>Vesta Teleradiology | freestyle libre</title>
	<link>https://vestarad.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>What Healthcare Providers Need to Know About FDA-Cleared CGM Sensors During Imaging: A Guide to FreeStyle Libre 2 and 3</title>
		<link>https://vestarad.com/what-healthcare-providers-need-to-know-about-fda-cleared-cgm-sensors-during-imaging-a-guide-to-freestyle-libre-2-and-3/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-healthcare-providers-need-to-know-about-fda-cleared-cgm-sensors-during-imaging-a-guide-to-freestyle-libre-2-and-3</link>
					<comments>https://vestarad.com/what-healthcare-providers-need-to-know-about-fda-cleared-cgm-sensors-during-imaging-a-guide-to-freestyle-libre-2-and-3/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Mon, 03 Mar 2025 22:33:04 +0000</pubDate>
				<category><![CDATA[Blog updates]]></category>
		<category><![CDATA[Health News]]></category>
		<category><![CDATA[blood glucose monitoring]]></category>
		<category><![CDATA[cgm]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[diabetes patients]]></category>
		<category><![CDATA[freestyle libre]]></category>
		<category><![CDATA[mri procedures]]></category>
		<category><![CDATA[sensors]]></category>
		<category><![CDATA[teleradiology companies]]></category>
		<category><![CDATA[teleradiology company]]></category>
		<category><![CDATA[xray]]></category>
		<guid isPermaLink="false">https://vestarad.com/?p=5018</guid>

					<description><![CDATA[<p>In a significant advancement for diabetes care, the U.S. Food and Drug Administration (FDA) has granted clearance for Abbott&#8217;s FreeStyle Libre 2 and 3 continuous glucose monitoring (CGM) systems to be worn during common imaging procedures, including X-rays, CT scans, and MRIs. This development marks the first time CGM sensors can remain in place during &#8230; <a href="https://vestarad.com/what-healthcare-providers-need-to-know-about-fda-cleared-cgm-sensors-during-imaging-a-guide-to-freestyle-libre-2-and-3/" class="more-link">Continue reading<span class="screen-reader-text"> "What Healthcare Providers Need to Know About FDA-Cleared CGM Sensors During Imaging: A Guide to FreeStyle Libre 2 and 3"</span></a></p>
<p>The post <a href="https://vestarad.com/what-healthcare-providers-need-to-know-about-fda-cleared-cgm-sensors-during-imaging-a-guide-to-freestyle-libre-2-and-3/">What Healthcare Providers Need to Know About FDA-Cleared CGM Sensors During Imaging: A Guide to FreeStyle Libre 2 and 3</a> first appeared on <a href="https://vestarad.com">Vesta Teleradiology</a>.</p>]]></description>
										<content:encoded><![CDATA[<p><span style="font-weight: 400;">In a significant advancement for diabetes care, the U.S. Food and Drug Administration (FDA) has granted clearance</span><a href="https://abbott.mediaroom.com/press-releases?item=124675" target="_blank" rel="noopener"> <span style="font-weight: 400;">for Abbott&#8217;s FreeStyle Libre 2 and 3 continuous glucose monitoring (CGM) systems</span></a><span style="font-weight: 400;"> to be worn during common imaging procedures, including X-rays, CT scans, and MRIs. This development marks the</span><a href="https://www.mpo-mag.com/breaking-news/fda-oks-abbotts-freestyle-2-3-cgms-for-use-during-imaging/" target="_blank" rel="noopener"> <span style="font-weight: 400;">first time</span></a><span style="font-weight: 400;"> CGM sensors can remain in place during such tests, offering enhanced convenience and continuous glucose monitoring for patients. ​</span></p>
<h3><b>Implications for Healthcare Providers</b></h3>
<p><span style="font-weight: 400;">As healthcare professionals, it&#8217;s essential to understand the nuances of this FDA clearance to guide patient care effectively:​</span></p>
<ul>
<li style="font-weight: 400;" aria-level="1"><b>Enhanced Patient Convenience</b><span style="font-weight: 400;">: Previously, patients were required to remove their CGM sensors before imaging procedures, leading to potential data gaps and the inconvenience of sensor replacement. With this clearance, patients using FreeStyle Libre 2 and 3 systems can maintain continuous glucose monitoring during imaging, reducing disruptions in</span><a href="https://hitconsultant.net/2024/10/30/abbotts-freestyle-libre-cgm-systems-now-cleared-for-use-during-imaging-procedures/" target="_blank" rel="noopener"> <span style="font-weight: 400;">diabetes management</span></a><span style="font-weight: 400;"><span style="font-weight: 400;">.</span></span></li>
<li style="font-weight: 400;" aria-level="1"><b>Safety Considerations</b><span style="font-weight: 400;">: While the sensors are now approved for use during imaging procedures, it&#8217;s crucial to note that sensor readings may be compromised during an MRI. However, system function is expected to return to normal within one hour post-procedure. ​</span></li>
</ul>
<h3><b>Guidance for Patient Communication</b></h3>
<p><span style="font-weight: 400;">Effective communication with patients regarding this development is vital:​</span></p>
<ul>
<li style="font-weight: 400;" aria-level="1"><b>Pre-Procedure Consultation</b><span style="font-weight: 400;"><span style="font-weight: 400;">: Encourage patients to inform all members of their healthcare team about their use of the FreeStyle Libre 2 or 3 systems prior to scheduling imaging procedures. This ensures coordinated care and appropriate precautions during the imaging process.​</span></span></li>
<li style="font-weight: 400;" aria-level="1"><b>Setting Expectations</b><span style="font-weight: 400;"><span style="font-weight: 400;">: Inform patients that while they can keep their CGM sensors on during imaging tests, there may be temporary compromises in sensor readings, especially during MRIs. Reassure them that normal sensor function typically resumes within an hour after the procedure.​</span></span></li>
<li style="font-weight: 400;" aria-level="1"><b>Post-Procedure Monitoring</b><span style="font-weight: 400;">: Advise patients to closely monitor their glucose levels following imaging procedures and to report any anomalies or concerns promptly.​</span></li>
</ul>
<h3><b>Operational Considerations for Healthcare Facilities</b></h3>
<p><span style="font-weight: 400;">To integrate this new clearance into practice effectively:​</span></p>
<ul>
<li style="font-weight: 400;" aria-level="1"><b>Staff Education</b><span style="font-weight: 400;"><span style="font-weight: 400;">: Ensure that radiology and imaging department staff are informed about the FDA clearance and understand that patients with FreeStyle Libre 2 and 3 sensors can undergo imaging without removing their devices.​</span></span></li>
</ul>
<ul>
<li style="font-weight: 400;" aria-level="1"><b>Protocol Updates</b><span style="font-weight: 400;"><span style="font-weight: 400;">: Revise existing imaging protocols to reflect this change, ensuring that all relevant personnel are aware and that patient workflows are adjusted accordingly.​</span></span></li>
<li style="font-weight: 400;" aria-level="1"><b>Equipment Compatibility</b><span style="font-weight: 400;"><span style="font-weight: 400;">: While the sensors are approved for use during imaging, remain vigilant about the specific conditions outlined by Abbott, especially concerning MRI procedures. Ensure that imaging equipment settings align with the recommended parameters to maintain patient safety and device integrity. ​</span></span><img fetchpriority="high" decoding="async" class="aligncenter size-full wp-image-4588" src="https://vestarad.com/wp-content/uploads/2023/08/mri-demand-growth.jpg" alt="" width="640" height="427" srcset="https://vestarad.com/wp-content/uploads/2023/08/mri-demand-growth.jpg 640w, https://vestarad.com/wp-content/uploads/2023/08/mri-demand-growth-300x200.jpg 300w" sizes="(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 984px) 61vw, (max-width: 1362px) 45vw, 600px" /></li>
</ul>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><span style="font-weight: 400;">By staying informed and updating clinical practices, healthcare providers like those in radiology centers, <a href="https://vestarad.com/why-ers-can-see-an-influx-of-patients-this-summer/">emergency rooms</a> and VA medical centers can enhance patient care, reduce disruptions in diabetes management, and ensure safety during imaging procedures involving CGM devices.</span></p>
<p><span style="font-weight: 400;"> </span></p>
<p>&nbsp;</p><p>The post <a href="https://vestarad.com/what-healthcare-providers-need-to-know-about-fda-cleared-cgm-sensors-during-imaging-a-guide-to-freestyle-libre-2-and-3/">What Healthcare Providers Need to Know About FDA-Cleared CGM Sensors During Imaging: A Guide to FreeStyle Libre 2 and 3</a> first appeared on <a href="https://vestarad.com">Vesta Teleradiology</a>.</p>]]></content:encoded>
					
					<wfw:commentRss>https://vestarad.com/what-healthcare-providers-need-to-know-about-fda-cleared-cgm-sensors-during-imaging-a-guide-to-freestyle-libre-2-and-3/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
